The Exchange has sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Cohance Lifesciences to clarify discrepancies found in the XBRL-formatted financial results submitted for the quarter ended 30 September 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has not yet responded. XBRL is the standard digital format companies use to file financial results with the exchange, so this typically relates to data tagging or formatting errors rather than the underlying financials. The exchange's query is pending the company's reply.
This is a routine compliance clarification and does not indicate any financial irregularity or penalty at this stage. Shareholders should monitor for the company's response, but there is likely no material impact on the stock unless the issue escalates.